Decade in review--dyslipidaemia: Resurgence of targets and compounds to treat dyslipidaemia

Research output: Contribution to journalEditorialAcademicpeer-review

8 Citations (Scopus)

Abstract

Over the past decade, we have witnessed the unparalleled success of statins to treat dyslipidaemia. Target identification by Mendelian randomization, human monoclonal antibodies, gene therapy, RNA-based targets, and atherogenic lipoproteins other than LDL cholesterol have fuelled intense development efforts that might bear fruit in the very near future
Original languageEnglish
Pages (from-to)629-631
JournalNature Reviews. Cardiology
Volume11
Issue number11
DOIs
Publication statusPublished - 2014

Cite this